$TBPH
Theravance Biopharma Inc Stock $tbph

$tbph Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000155837022002373 Filed on February 28, 2022

Income Statement

Concept	2021 Q4	2021 Q3	2021
Revenue	$14.95M	$13.19M	$55.31M
YoY Change	-20.2%	-27.73%	-23.03%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$39.11M	$21.30M	$99.30M
YoY Change	29.93%	-22.55%	-8.62%
% of Gross Profit
Research & Development	$31.23M	$43.74M	$193.7M
YoY Change	-52.11%	-35.08%	-25.79%
% of Gross Profit
Depreciation & Amortization	$1.361M	$1.625M	$3.500M
YoY Change	-3.48%	19.49%	6.06%
% of Gross Profit
Operating Expenses	$71.11M	$66.81M	$313.1M
YoY Change	-25.32%	-29.58%	-15.29%
Operating Profit	-$56.17M	-$53.62M	-$257.8M
YoY Change	-26.57%	-30.02%	-13.42%
Interest Expense	$23.98M	$11.74M	$46.89M
YoY Change	157.87%	1.46%	5.17%
% of Operating Profit
Other Income/Expense, Net		-$166.0K	$1.109M
YoY Change		-113.44%	-60.83%
Pretax Income	-$32.19M	-$35.32M	-$199.6M
YoY Change	-52.11%	-51.99%	-30.35%
Income Tax	-$151.0K	-$7.000K	-$200.0K
% Of Pretax Income
Net Earnings	-$32.03M	-$35.31M	-$199.4M
YoY Change	-45.18%	-52.06%	-28.27%
Net Earnings / Revenue	-214.33%	-267.61%	-360.55%
Basic Earnings Per Share	-$0.43	-$0.48	-$2.87
Diluted Earnings Per Share	-$0.43	-$0.48	-$2.87
COMMON SHARES
Basic Shares Outstanding	73.70M	73.57M	69.46M
Diluted Shares Outstanding		73.57M	69.46M

Balance Sheet

Concept	2021 Q4	2021 Q3	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$173.5M	$216.2M	$173.5M
YoY Change	-40.79%	-39.66%	-40.78%
Cash & Equivalents	$89.96M	$121.4M	$89.96M
Short-Term Investments	$83.51M	$94.79M	$83.51M
Other Short-Term Assets	$18.81M	$23.19M	$18.81M
YoY Change	-38.74%	-25.45%	-38.74%
Inventory
Prepaid Expenses
Receivables	$14.07M	$14.00M	$14.07M
Other Receivables	$43.53M	$43.77M	$43.53M
Total Short-Term Assets	$249.9M	$297.2M	$249.9M
YoY Change	-36.47%	-34.07%	-36.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.66M	$16.00M	$53.35M
YoY Change	-16.84%	3.71%	-10.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$67.54M	$45.09M	$67.54M
YoY Change	429.7%		427.63%
Other Assets	$3.228M	$3.297M	$4.065M
YoY Change	31.7%	307.04%	23.18%
Total Long-Term Assets	$124.9M	$105.9M	$124.9M
YoY Change	65.02%	72.36%	64.84%
TOTAL ASSETS
Total Short-Term Assets	$249.9M	$297.2M	$249.9M
Total Long-Term Assets	$124.9M	$105.9M	$124.9M
Total Assets	$374.8M	$403.1M	$374.8M
YoY Change	-20.09%	-21.3%	-20.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.098M	$8.900M	$3.098M
YoY Change	-54.27%	38.16%	-54.44%
Accrued Expenses	$38.45M	$41.75M	$38.45M
YoY Change	-55.24%	-47.55%	-55.24%
Deferred Revenue	$98.00K	$2.902M
YoY Change	-99.15%	-84.06%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$16.94M	$12.53M	$16.94M
YoY Change	-12.23%		-12.23%
Total Short-Term Liabilities	$58.59M	$66.08M	$58.59M
YoY Change	-52.59%	-36.62%	-52.6%
LONG-TERM LIABILITIES
Long-Term Debt	$599.4M	$603.3M	$599.4M
YoY Change	-0.07%	-1.29%	-0.07%
Other Long-Term Liabilities	$2.420M	$2.609M	$55.41M
YoY Change	32.02%	-73.11%	12.17%
Total Long-Term Liabilities	$2.420M	$2.609M	$654.8M
YoY Change	32.02%	-73.11%	0.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$58.59M	$66.08M	$58.59M
Total Long-Term Liabilities	$2.420M	$2.609M	$654.8M
Total Liabilities	$61.01M	$68.69M	$713.4M
YoY Change	-51.35%	-39.73%	-7.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.726B	-$1.694B
YoY Change	13.06%	15.38%
Common Stock	$1.000K	$1.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$338.6M	-$323.6M	-$338.6M
YoY Change
Total Liabilities & Shareholders Equity	$374.8M	$403.1M	$374.8M
YoY Change	-20.09%	-21.3%	-20.1%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021
OPERATING ACTIVITIES
Net Income	-$32.03M	-$35.31M	-$199.4M
YoY Change	-45.18%	-52.06%	-28.27%
Depreciation, Depletion And Amortization	$1.361M	$1.625M	$3.500M
YoY Change	-3.48%	19.49%	6.06%
Cash From Operating Activities	-$42.43M	-$45.45M	-$207.9M
YoY Change	-34.64%	-41.0%	-16.99%
INVESTING ACTIVITIES
Capital Expenditures	-$444.0K	-$1.039M	-$3.406M
YoY Change	-64.48%	-49.32%	-48.55%
Acquisitions
YoY Change
Other Investing Activities	$11.27M	-$34.75M	$127.9M
YoY Change	-78.99%	-150.68%	637.6%
Cash From Investing Activities	$10.82M	-$35.79M	$124.5M
YoY Change	-79.33%	-153.79%	1061.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$108.2M
YoY Change			-22.68%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	149.0K	-2.286M	91.86M
YoY Change	-80.13%	135.67%	-65.08%
NET CHANGE
Cash From Operating Activities	-42.43M	-45.45M	-207.9M
Cash From Investing Activities	10.82M	-35.79M	124.5M
Cash From Financing Activities	149.0K	-2.286M	91.86M
Net Change In Cash	-31.46M	-83.53M	8.496M
YoY Change	166.62%	628.84%	-63.7%
FREE CASH FLOW
Cash From Operating Activities	-$42.43M	-$45.45M	-$207.9M
Capital Expenditures	-$444.0K	-$1.039M	-$3.406M
Free Cash Flow	-$41.99M	-$44.41M	-$204.5M
YoY Change	-34.05%	-40.77%	-16.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69461000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62345000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55610000
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityCurrent
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001583107
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69461000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62345000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55610000
CY2020Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	64328000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74435000
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.87
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.46
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.25
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.87
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.46
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.25
CY2021	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2019Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityCurrent
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.24
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.80
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.40
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.00
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.16
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-36033
CY2021	dei	Entity Registrant Name EntityRegistrantName	THERAVANCE BIOPHARMA, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	KY
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1226628
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	P.O. Box 309
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Ugland House, South Church Street
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	George Town, Grand Cayman
CY2021	dei	Entity Address Country EntityAddressCountry	KY
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	KY1-1104
CY2021	dei	City Area Code CityAreaCode	650
CY2021	dei	Local Phone Number LocalPhoneNumber	808-6000
CY2021	dei	Security12b Title Security12bTitle	Ordinary Share $0.00001 Par Value
CY2021	dei	Trading Symbol TradingSymbol	TBPH
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2451000
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	882100000
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74696687
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	89959000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81467000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	83506000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	211474000
CY2021Q4	tbph	Receivables From Collaboration Partners ReceivablesFromCollaborationPartners	14065000
CY2020Q4	tbph	Receivables From Collaboration Partners ReceivablesFromCollaborationPartners	15868000
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	43534000
CY2020Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	53799000
CY2021Q4	tbph	Prepaid Clinical And Development Services PrepaidClinicalAndDevelopmentServices	10245000
CY2020Q4	tbph	Prepaid Clinical And Development Services PrepaidClinicalAndDevelopmentServices	20374000
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	8561000
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	10359000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	249870000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	393341000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13657000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16422000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39690000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	43260000
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	67537000
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	12750000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	837000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	833000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3228000
CY2021Q4	us-gaap	Assets Assets	374819000
CY2020Q4	us-gaap	Assets Assets	469057000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3098000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6775000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12796000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	35238000
CY2021Q4	tbph	Accrued Clinical And Development Expenses Current AccruedClinicalAndDevelopmentExpensesCurrent	17010000
CY2020Q4	tbph	Accrued Clinical And Development Expenses Current AccruedClinicalAndDevelopmentExpensesCurrent	28799000
CY2021Q4	tbph	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	2898000
CY2020Q4	tbph	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	6048000
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	3940000
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	3974000
CY2021Q4	tbph	Non Recourse Debt Due2035 Current NonRecourseDebtDue2035Current	16940000
CY2020Q4	tbph	Non Recourse Debt Due2035 Current NonRecourseDebtDue2035Current	19334000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	503000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9867000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	98000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11523000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1304000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2013000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	58587000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	123571000
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	228035000
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	226963000
CY2021Q4	tbph	Non Recourse Debt Due2035 Noncurrent NonRecourseDebtDue2035Noncurrent	371359000
CY2020Q4	tbph	Non Recourse Debt Due2035 Noncurrent NonRecourseDebtDue2035Noncurrent	372873000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	52681000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47220000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	310000
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	348000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2420000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1222818000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	47000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1726043000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1526617000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-338573000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-303751000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	374819000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1833000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	230000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	230000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74435000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	64328000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1387469000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	469057000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55311000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	71857000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	73414000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	193657000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	260953000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	219248000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	99296000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	108661000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	106081000
CY2021	us-gaap	Restructuring Charges RestructuringCharges	20142000
CY2021	us-gaap	Operating Expenses OperatingExpenses	313095000
CY2020	us-gaap	Operating Expenses OperatingExpenses	369614000
CY2019	us-gaap	Operating Expenses OperatingExpenses	325329000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-257784000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-297757000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-251915000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	103987000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	68438000
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	33705000
CY2021	us-gaap	Interest Expense InterestExpense	46889000
CY2020	us-gaap	Interest Expense InterestExpense	44585000
CY2019	us-gaap	Interest Expense InterestExpense	31862000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-15464000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1109000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2831000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8395000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-199577000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-286537000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-241677000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-151000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8520000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5222000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-199426000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-278017000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-236455000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.87
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.46
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.25
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69461000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62345000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55610000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	62061000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	62976000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	60450000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-199426000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-278017000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-236455000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-47000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-98000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	311000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-199473000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-278115000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-236144000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-51589000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3474000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	60450000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3142000
CY2019	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3173000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	311000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-236455000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-223840000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-223840000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	139915000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3701000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	62976000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1361000
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	9749000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-98000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-278017000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-303751000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-303751000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	108180000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3466000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	62061000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	9061000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-47000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-199426000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-338573000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-199426000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-278017000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-236455000
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	5912000
CY2020	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	6798000
CY2019	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	6441000
CY2021	tbph	Amortization And Accretion Income AmortizationAndAccretionIncome	-10000
CY2020	tbph	Increase Decrease In Receivables From Collaboration Partners IncreaseDecreaseInReceivablesFromCollaborationPartners	-6128000
CY2019	tbph	Increase Decrease In Receivables From Collaboration Partners IncreaseDecreaseInReceivablesFromCollaborationPartners	11943000
CY2021	tbph	Increase Decrease In Prepaid Clinical And Development Services IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices	-10129000
CY2020	tbph	Increase Decrease In Prepaid Clinical And Development Services IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices	17638000
CY2019	tbph	Increase Decrease In Prepaid Clinical And Development Services IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices	561000
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-2867000
CY2020	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	2327000
CY2020	tbph	Amortization And Accretion Income AmortizationAndAccretionIncome	1079000
CY2019	tbph	Amortization And Accretion Income AmortizationAndAccretionIncome	3451000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	62061000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	62976000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	60450000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-39000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	3786000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	3344000
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	3224000
CY2021	tbph	Gain Loss On Modification Of Lease GainLossOnModificationOfLease	1863000
CY2021	tbph	Equity Method Investments Undistributed Earnings EquityMethodInvestmentsUndistributedEarnings	44516000
CY2020	tbph	Equity Method Investments Undistributed Earnings EquityMethodInvestmentsUndistributedEarnings	37975000
CY2019	tbph	Equity Method Investments Undistributed Earnings EquityMethodInvestmentsUndistributedEarnings	23152000
CY2021	tbph	Interest Shortfall On2035 Notes InterestShortfallOn2035Notes	5713000
CY2020	tbph	Interest Shortfall On2035 Notes InterestShortfallOn2035Notes	17643000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-15464000
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-10000
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	95000
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-146000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-620000
CY2021	tbph	Increase Decrease In Receivables From Collaboration Partners IncreaseDecreaseInReceivablesFromCollaborationPartners	-1803000
CY2019	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	73000
CY2020	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	258000
CY2019	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	3700000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	972000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	852000
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	358000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3534000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3658000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4274000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-37225000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5983000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	10626000
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-34000
CY2020	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-1685000
CY2019	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	2573000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-11463000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-26465000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-31245000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1742000
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	1600000
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	423898000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	286199000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	399318000
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	5326000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	158305000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	401987000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	139915000
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	380000000
CY2019	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2317000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	587000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-7606000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-4748000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-207858000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-250403000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-238197000
CY2021	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	3406000
CY2020	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	6616000
CY2019	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	3176000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	339018000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	19942000
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	6000
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	64000
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	5000
CY2019	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	5000000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	124494000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10721000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-83051000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	108180000
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	10730000
CY2020	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	11470000
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	235347000
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2152000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3466000
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3701000
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3474000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1361000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3142000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	9061000
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	9749000
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3173000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	91860000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	263085000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1291000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8496000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23403000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-319957000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82300000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	26178000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-4089000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	14000
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	22000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	49847000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58897000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	378854000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90796000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82300000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58897000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	39029000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	24024000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</p>
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company invests in a variety of financial instruments and, based on its policy, limits the amount of credit exposure with any one issuer, industry or geographic area for investments other than instruments backed by the US federal government. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company’s receivables primarily relate to amounts due under its collaboration and licensing agreements. Accordingly, the Company may be exposed to credit risk generally associated with pharmaceutical companies or specific to its collaboration agreements. The Company performs periodic evaluations of its customers and generally does not require collateral. For the year ended December 31, 2021, 2020, and 2019, the Company did not experience any material losses related to its receivables.</p>
CY2019	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2020	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2021	us-gaap	Advertising Expense AdvertisingExpense	9300000
CY2020	us-gaap	Advertising Expense AdvertisingExpense	6300000
CY2019	us-gaap	Advertising Expense AdvertisingExpense	2400000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	75000000.0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	63400000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-199426000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-278017000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-236455000
CY2021	tbph	Weighted Average Number Of Shares Outstanding Before Forfeitures WeightedAverageNumberOfSharesOutstandingBeforeForfeitures	69518000
CY2020	tbph	Weighted Average Number Of Shares Outstanding Before Forfeitures WeightedAverageNumberOfSharesOutstandingBeforeForfeitures	62808000
CY2019	tbph	Weighted Average Number Of Shares Outstanding Before Forfeitures WeightedAverageNumberOfSharesOutstandingBeforeForfeitures	56452000
CY2021	tbph	Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture	-57000
CY2020	tbph	Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture	-463000
CY2019	tbph	Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture	-842000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69461000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62345000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55610000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.87
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.46
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.25
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14145000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13229000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13253000
CY2021	tbph	Collaborative Arrangements Revenue CollaborativeArrangementsRevenue	11463000
CY2020	tbph	Collaborative Arrangements Revenue CollaborativeArrangementsRevenue	26464000
CY2019	tbph	Collaborative Arrangements Revenue CollaborativeArrangementsRevenue	31245000
CY2018Q1	tbph	Profit Loss Percentage As Per Collaboration Agreement ProfitLossPercentageAsPerCollaborationAgreement	0.33
CY2021	tbph	Profit Loss Percentage As Per Collaboration Agreement ProfitLossPercentageAsPerCollaborationAgreement	0.35
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	833000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90796000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82300000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58897000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-900000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-300000
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	200000
CY2021	tbph	Collaborative Arrangement Research And Development Expenses Reimbursed To Entity CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity	7891000
CY2020	tbph	Collaborative Arrangement Research And Development Expenses Reimbursed To Entity CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity	10078000
CY2019	tbph	Collaborative Arrangement Research And Development Expenses Reimbursed To Entity CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity	5589000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55311000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	71857000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	73414000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	89959000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81467000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58064000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	837000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	833000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	133738000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	133734000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	211427000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	53000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	211474000
CY2021	tbph	Marketable Securities Maximum Contractual Maturity Period MarketableSecuritiesMaximumContractualMaturityPeriod	P6M
CY2021	tbph	Marketable Securities Average Contractual Maturity Period MarketableSecuritiesAverageContractualMaturityPeriod	P2M
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	35017000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	5000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	35017000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	5000
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	44420000
CY2021Q3	tbph	Sublease Monthly Base Rent SubleaseMonthlyBaseRent	100000
CY2021Q3	tbph	Sublease Percentage Of Increase In Annual Base Rent SubleasePercentageOfIncreaseInAnnualBaseRent	0.03
CY2021Q3	us-gaap	Sublease Income SubleaseIncome	13100000
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	6000
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	44420000
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	6000
CY2021Q4	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	0
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	19900000
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	616334000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	619170000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	7625000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	8732000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	44707000
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	42625000
CY2019	us-gaap	Interest Expense Debt InterestExpenseDebt	28811000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2182000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1960000
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3051000
CY2021	us-gaap	Interest Expense InterestExpense	46889000
CY2020	us-gaap	Interest Expense InterestExpense	44585000
CY2019	us-gaap	Interest Expense InterestExpense	31862000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-15500000
CY2021Q4	tbph	Area Of Leased Space AreaOfLeasedSpace	162000
CY2021	tbph	Number Of Building Leased NumberOfBuildingLeased	2
CY2020Q4	tbph	Tenant Improvement Allowance TenantImprovementAllowance	12100000
CY2021Q3	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	8000
CY2021Q3	tbph	Increase Decrease In Operating Lease Asset IncreaseDecreaseInOperatingLeaseAsset	-1100000
CY2021Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3000000.0
CY2021Q3	tbph	Gain Loss On Modification Of Lease GainLossOnModificationOfLease	1900000
CY2021Q3	tbph	Area Of Property Subleased AreaOfPropertySubleased	21000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39690000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	8123000
CY2021Q3	tbph	Premium Over Proportionate Lease Payment Obligations PremiumOverProportionateLeasePaymentObligations	3800000
CY2021Q3	tbph	Percentage Of Excess Sublease Payments Received Shared With Lessor PercentageOfExcessSubleasePaymentsReceivedSharedWithLessor	0.50
CY2021Q3	tbph	Premium Over Proportionate Lease Payment Obligations Shared With Lessor PremiumOverProportionateLeasePaymentObligationsSharedWithLessor	1900000
CY2021Q3	tbph	Percentage Of Excess Sublease Payments Received Retained PercentageOfExcessSubleasePaymentsReceivedRetained	0.50
CY2021	tbph	Number Of Options To Extend NumberOfOptionsToExtend	2
CY2021Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	43260000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	503000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9867000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	52681000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47220000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	53184000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	57087000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	8971000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	3804000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9390000
CY2021Q4	us-gaap	Restructuring Reserve RestructuringReserve	9550000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9655000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	9865000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10133000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10425000
CY2021	us-gaap	Depreciation Depreciation	3500000
CY2020	us-gaap	Depreciation Depreciation	3300000
CY2019	us-gaap	Depreciation Depreciation	3300000
CY2014Q2	tbph	Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans	3
CY2021Q3	tbph	Share Based Compensation Allocation Of Recognized Period Costs Capitalized Reversed Amount ShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedReversedAmount	2800000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	2800000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	36552000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	86020000
CY2021Q4	tbph	Tenant Improvement Allowance TenantImprovementAllowance	10214000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	22622000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	53184000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y3M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0864
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	52149000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	62230000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	38492000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	45808000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13657000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16422000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	62061000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	62976000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	60450000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	62061000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	62976000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	60450000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	82821000
CY2021Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	19409000
CY2020Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	19409000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	93551000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	28372000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	24075000
CY2021Q4	tbph	Deferred Tax Assets Property Plant And Equipment And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets	287177000
CY2020Q4	tbph	Deferred Tax Assets Property Plant And Equipment And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets	310187000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10432000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	15087000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3590000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	8145000
CY2021Q4	tbph	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	11607000
CY2020Q4	tbph	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	11662000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	10505000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	346000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-199577000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-286537000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-241677000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-151000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-8520000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-5222000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-151000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8520000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5222000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0008
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0297
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0216
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8500000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5200000
CY2021Q4	us-gaap	Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries	0
CY2020Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	0
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	115606000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	486698000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	471732000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	477868000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	462711000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8830000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	9021000
CY2021Q4	tbph	Deferred Tax Liabilities Operating Lease Assets DeferredTaxLiabilitiesOperatingLeaseAssets	8575000
CY2020Q4	tbph	Deferred Tax Liabilities Operating Lease Assets DeferredTaxLiabilitiesOperatingLeaseAssets	8680000
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	254000
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	341000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8830000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	9021000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	462700000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	477900000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	58763000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	8059000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	12743000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	63447000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	395000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	11971000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	75023000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	75000000.0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	63400000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-79679000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-52405000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-35308000
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-32034000
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.24
CY2021Q4	tbph	Guarantees And Indemnifications Liability GuaranteesAndIndemnificationsLiability	0
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	92338000
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	87184000
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	94872000
CY2021Q2	us-gaap	Share Price SharePrice	15.00
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7705000
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	115600000
CY2021Q3	tbph	Percentage Of Reduction In Workforce PercentageOfReductionInWorkforce	0.75
CY2021Q3	tbph	Number Of Employees Reduction In Workforce NumberOfEmployeesReductionInWorkforce	270
CY2021Q4	tbph	Percentage Of Reduction In Workforce PercentageOfReductionInWorkforce	0.75
CY2021Q4	us-gaap	Restructuring And Related Cost Expected Cost1 RestructuringAndRelatedCostExpectedCost1	17000000.0
CY2021	tbph	Non Cash Charges Related To Modification Of Equity Awards For Terminated And Remaining Employee NonCashChargesRelatedToModificationOfEquityAwardsForTerminatedAndRemainingEmployee	15000000.0
CY2021	us-gaap	Restructuring Charges RestructuringCharges	20100000
CY2021	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	11867000
CY2021	us-gaap	Payments For Restructuring PaymentsForRestructuring	2317000
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14257000
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12914000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13194000
CY2021Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14946000
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	98149000
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	77024000
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	66809000
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	71113000
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-83892000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-64110000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-53615000
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-56167000
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19862000
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15008000
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18257000
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18730000
CY2020Q4	us-gaap	Operating Expenses OperatingExpenses	95220000
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-72476000
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-72176000
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-76615000
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-76490000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-83053000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-62887000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-73643000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-58434000
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.40
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.00
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.16
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
CY2021	tbph	Profit Loss Percentage As Per Collaboration Agreement ProfitLossPercentageAsPerCollaborationAgreement	0.35
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Redwood City, California

Files In Submission

Name	View Source	Status
0001558370-22-002373-index-headers.html	Edgar Link	pending
0001558370-22-002373-index.html	Edgar Link	pending
0001558370-22-002373.txt	Edgar Link	pending
0001558370-22-002373-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tbph-20211231.xsd	Edgar Link	pending
tbph-20211231x10k.htm	Edgar Link	pending
tbph-20211231x10k006.jpg	Edgar Link	pending
tbph-20211231x10k008.jpg	Edgar Link	pending
tbph-20211231x10k_htm.xml	Edgar Link	completed
tbph-20211231xex10d69.htm	Edgar Link	pending
tbph-20211231xex10d70.htm	Edgar Link	pending
tbph-20211231xex10d71.htm	Edgar Link	pending
tbph-20211231xex10d72.htm	Edgar Link	pending
tbph-20211231xex10d72001.jpg	Edgar Link	pending
tbph-20211231xex10d72002.jpg	Edgar Link	pending
tbph-20211231xex10d72003.jpg	Edgar Link	pending
tbph-20211231xex10d72005.jpg	Edgar Link	pending
tbph-20211231xex21d1.htm	Edgar Link	pending
tbph-20211231xex23d1.htm	Edgar Link	pending
tbph-20211231xex23d2.htm	Edgar Link	pending
tbph-20211231xex31d1.htm	Edgar Link	pending
tbph-20211231xex31d2.htm	Edgar Link	pending
tbph-20211231xex32.htm	Edgar Link	pending
tbph-20211231_cal.xml	Edgar Link	unprocessable
tbph-20211231_def.xml	Edgar Link	unprocessable
tbph-20211231_lab.xml	Edgar Link	unprocessable
tbph-20211231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TBPH
Theravance Biopharma Inc Stock $tbph

2021 Q4 Form 10-K Financial Statement

#000155837022002373 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TBPH Theravance Biopharma Inc Stock $tbph

2021 Q4 Form 10-K Financial Statement

#000155837022002373 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TBPH
Theravance Biopharma Inc Stock $tbph